Elanco begins phased U.S. launch of Befrena for canine dermatitis: full analysis
Elanco is moving deeper into canine dermatology with the phased U.S. launch of Befrena (tirnovetmab), an anti-IL-31 monoclonal antibody injection for dogs with allergic and atopic dermatitis. The launch was announced May 18, 2026, after USDA approval on December 31, 2025, and comes as allergy season intensifies and clinics continue to manage high demand for faster itch relief. (prnewswire.com)
The product has been in view for months. Elanco had previously told investors it expected a first-half 2026 launch, and the company highlighted Befrena as one of its major innovation drivers after securing approval in late 2025. In its 2025 annual report and 2026 investor materials, Elanco tied Befrena to a broader dermatology strategy that also includes Zenrelia, its oral JAK inhibitor for canine allergic skin disease. (s1.q4cdn.com)
The regulatory pathway is part of what makes Befrena notable. USDA APHIS, through the Center for Veterinary Biologics, regulates veterinary biologics used to prevent, diagnose, or treat animal diseases through immunological mechanisms. That differs from Zenrelia, which the FDA approved in September 2024 as an oral JAK inhibitor for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 1 year old. (aphis.usda.gov)
On product specifics, Elanco says Befrena is indicated for canine allergic and atopic dermatitis, begins controlling itch within 24 hours, and carries a recommended dosing interval of 6 to 8 weeks. The company has also said the product is entering clinics first through an Early Experience Program, with select veterinarians and veterinary dermatologists already using it. In launch materials, Elanco framed Befrena as a new option in the roughly $1.3 billion U.S. canine dermatology market. (prnewswire.com)
Early expert commentary has so far come mainly through company materials. Elanco said veterinarians in the Early Experience Program have reported initial improvement in itchy dogs, and identified Jason Pieper, a veterinary dermatologist and associate professor at Iowa State University’s College of Veterinary Medicine, among clinicians involved in early use. Independent third-party reaction appears limited so far, which is common in the first days of a phased commercial launch. That means much of the near-term conversation is likely to center on real-world response, duration, case selection, and how clinics position the product relative to established therapies. (prnewswire.com)
Why it matters: For veterinary professionals, Befrena gives practices another targeted option for chronic pruritus management at a time when canine dermatology remains one of small animal medicine’s most persistent workflow and compliance challenges. A longer labeled dosing interval may appeal to clinics trying to balance efficacy, revisit cadence, and pet parent adherence, while Elanco’s expanding dermatology lineup could also intensify commercial competition in a category where treatment choice is often shaped by speed of relief, safety considerations, route of administration, and patient history. That context matters even more because Zenrelia’s FDA approval came with a boxed warning around vaccination timing and immunosuppression, which may influence how some clinicians think about sequencing or selecting therapies in certain dogs. (investor.elanco.com)
What to watch: The next signals will be practical ones: how quickly the phased launch broadens beyond early-access sites, whether Elanco publishes additional field-use or comparative data, and how general practitioners and dermatologists incorporate Befrena into multimodal allergy protocols during the 2026 allergy season. Uptake will likely depend less on launch messaging than on repeatability in practice, clinic economics, and whether pet parents see durable improvement between visits. (prnewswire.com)